Ask Warren

Kolon TissueGene

950160 · KOSDAQ · ₩950160 · 코오롱티슈진

₩14,760▲ ₩40 (0.27%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −68.70%
Market cap
₩1.3T
Enterprise value
₩1.3T
P/E
—
P/B
9,471.4×
Dividend yield
0.0%
ROE
−46.6%
Net margin
−1,863.5%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−90.1% from the high

₩11,470Today: ₩14,210 – ₩15,230₩149,000

Returns

  • 1W−4.5%
  • 1M−6.6%
  • 3M+1.4%
  • 6M−86.2%
  • YTD−81.5%
  • 1Y−68.7%
Volume today
213,940
0.4× the 20-day average
Traded today
₩3.2B
Listed shares
84,970,160
EPS (12 months)
−₩1
Earnings yield −0.0%
SellBuy
AI research · InitiationKolon TissueGene: Tiny Revenue, Persistent Losses and a Sharp Share Price DeclineThe filed numbers show a company with minimal revenue, recurring losses and a market value far above what its financials support, while the DCF model estimate is ₩0 per share.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

30Quiet
  • BuzzQuietBuzz 30 of 100 (50 is a normal day for this stock).
  • MomentumFlat-3.7% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 27: buy ₩423M at the close (5.1% of 20-day average trading value)

Sep 28Last 20 trading days (% of average trading value)Oct 27

On its 34 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 5.4% of trading value and pointed the same way 26 of 34 times.

  • 2× KODEX KOSDAQ150 Leverage ₩345M
  • 2× TIGER KOSDAQ150 Leverage ₩41M
  • -1× KODEX KOSDAQ150 Futures Inverse ₩24M
  • 2× RISE KOSDAQ150 Futures Leverage ₩7.2M
  • 2× KIWOOM KOSDAQ150 Futures Leverage ₩1.8M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

Kolon TissueGene stock overview

Kolon TissueGene (코오롱티슈진, KRX: 950160) is listed on KOSDAQ, in the Biotech & Pharma sector. S. Its shares closed at ₩14,760 on Oct 27, 2026, up 0.27% on the day, giving it a market value of ₩1.3T.

Key facts

Market cap
₩1.3T
Sector
Biotech & Pharma
Latest price change
+0.27%
As of
Oct 27, 2026
Main business
S.

Quick answers about Kolon TissueGene

What does Kolon TissueGene do?
S. FDA Phase 3 trials with 1,066 patients enrolled and follow-up ongoing. It also runs a composite distribution business selling health and beauty products and wine-related items through online and offline channels, which generated all of its reported revenue, and it targets patients in the United States.
What is the market cap of Kolon TissueGene?
The market capitalisation of Kolon TissueGene was ₩1.3T at the close on Oct 27, 2026.
Who are the largest shareholders of Kolon TissueGene?
According to the latest official filings, the largest reported holders are Kolon (65.51%, as of Sep 18, 2026); National Pension Service (0.57%, as of Dec 31, 2025); Noh Mun-jong (0.28%, as of Aug 6, 2026).
When is the next earnings report from Kolon TissueGene?
Korean companies rarely announce results dates in advance. Based on when Kolon TissueGene filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own Kolon TissueGene?
Yes. The National Pension Service held 0.57% of Kolon TissueGene shares as of Dec 31, 2025.

Company profile

The company develops TG-C, a cell and gene therapy for knee osteoarthritis that is designed to relieve pain and improve function, and is in U.S. FDA Phase 3 trials with 1,066 patients enrolled and follow-up ongoing. It also runs a composite distribution business selling health and beauty products and wine-related items through online and offline channels, which generated all of its reported revenue, and it targets patients in the United States.

Written by AI from the company's latest annual report.

Korean name
코오롱티슈진
Sector
Biotech & Pharma
Themes
Biotech (new drugs)
CEO
전승호
Founded
Jun 1999
Listed
Nov 2017
Listed shares
84,970,160
Fiscal year ends
Month 12
Website
tissuegene.com

Similar companies

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Kolon TissueGene / 코오롱티슈진 / 950160 / KRX:950160

Source: KRX statistical information